The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.
Siqing Fu
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Alberto Bessudo
No relevant relationships to disclose
Julie E. Bauman
No relevant relationships to disclose
Omid Hamid
No relevant relationships to disclose
Samir E. Witta
Consultant or Advisory Role - Curis
Grace K. Dy
No relevant relationships to disclose
Cheng Lai
Employment or Leadership Position - Curis
Stock Ownership - Curis
Robert Laliberte
Employment or Leadership Position - Curis
Maurizio Voi
Employment or Leadership Position - Curis
Stock Ownership - Curis